Eprodisate disodium

CAS No. 36589-58-9

Eprodisate disodium( Eprodisate Disodium | Eprodisate sodium | Kiacta )

Catalog No. M14258 CAS No. 36589-58-9

Eprodisate Disodium is the orally available disodium salt form of Eprodisate, a negatively charged sulfonated inhibitor of fibrillogenesis, that can be used in the treatment of amyloid A (AA) amyloidosis.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG 37 In Stock
1G 52 In Stock

Biological Information

  • Product Name
    Eprodisate disodium
  • Note
    Research use only, not for human use.
  • Brief Description
    Eprodisate Disodium is the orally available disodium salt form of Eprodisate, a negatively charged sulfonated inhibitor of fibrillogenesis, that can be used in the treatment of amyloid A (AA) amyloidosis.
  • Description
    Eprodisate Disodium is the orally available disodium salt form of Eprodisate, a negatively charged sulfonated inhibitor of fibrillogenesis, that can be used in the treatment of amyloid A (AA) amyloidosis.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Eprodisate Disodium | Eprodisate sodium | Kiacta
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    SAA
  • Research Area
    Other Indications
  • Indication
    ——

Chemical Information

  • CAS Number
    36589-58-9
  • Formula Weight
    248.19
  • Molecular Formula
    C3H6Na2O6S2
  • Purity
    >98% (HPLC)
  • Solubility
    Soluble in Water
  • SMILES
    O=S(CCCS(=O)([O-])=O)([O-])=O.[Na+].[Na+]
  • Chemical Name
    1,3-Propanedisulfonic acid, disodium salt

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Bayes M, et al. Methods Find Exp Clin Pharmacol. 2007 Apr;29(3):231-45.
molnova catalog
related products
  • Thiacloprid-Amid, Pe...

    Thiacloprid-Amid, Pestanal

  • β-Amyloid (31-35)

    β-Amyloid (31-35)

  • SKI II

    SKI II is a highly selective and non-ATP-competitive S1P receptor inhibitor (IC50: 0.5 μM) while exhibiting no inhibitory action on other kinases including PKCα, PI3K, and ERK2.